Vectibix
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Vectibix (panitumumab; Amgen/Takeda) is a fully human immunoglobulin G2 monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR). This prevents the activation of EGFR and halts the cascade of intracellular signals dependent on this receptor. Preclinical studies have shown that Vectibix results in inhibition of cell growth, induction of apoptosis, decreased pro-inflammatory cytokine and vascular growth factor production, and internalization of the EGFR.
TABLE OF CONTENTS
4 Product Profiles
4 Vectibix : Colorectal cancer (CRC)
LIST OF FIGURES
14 Figure 1: Vectibix for colorectal cancer – SWOT analysis
15 Figure 2: Datamonitor Healthcare’s drug assessment summary of Vectibix for colorectal cancer
16 Figure 3: Datamonitor Healthcare’s drug assessment summary of Vectibix for colorectal cancer
18 Figure 4: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
4 Table 1: Vectibix drug profile
6 Table 2: Overview of major approvals for Vectibix in colorectal cancer
7 Table 3: Vectibix pivotal trial data in colorectal cancer
13 Table 4: Vectibix early-phase data in colorectal cancer
19 Table 5: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
21 Table 6: Patients treated with Vectibix in the US, Japan, and five major EU markets, by country, 2016–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the